病毒学
生物
抗体
病毒
病毒进入
单克隆抗体
表位
中和抗体
脂质双层融合
维罗细胞
免疫学
病毒复制
作者
Iebe Rossey,Jason S. McLellan,Xavier Saelens,Bert Schepens
标识
DOI:10.1016/j.tim.2017.09.009
摘要
Most of the RSV-neutralizing activity in human serum is conferred by antibodies that specifically bind to prefusion F. The RSV-neutralizing activity of an antibody correlates with its affinity for prefusion F. The epitope of F-binding antibodies is often not restricted to one site. An increasing number of RSV F-specific monoclonal antibodies have been described, a few of which even neutralize closely related pneumoviruses. Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in the very young. The RSV fusion protein (F) is essential for virus entry because it mediates viral and host membrane fusion. During this fusion process F is converted from a metastable prefusion conformation into an energetically favored postfusion state. Antibodies that target F can prevent viral entry and reduce disease caused by RSV. During recent years, many prefusion F-specific antibodies have been described. These antibodies typically have stronger RSV-neutralizing activity compared to those that also bind F in the postfusion conformation. Here, we describe how F-specific antibodies protect against RSV and why specifically targeting prefusion F could have great clinical potential. Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in the very young. The RSV fusion protein (F) is essential for virus entry because it mediates viral and host membrane fusion. During this fusion process F is converted from a metastable prefusion conformation into an energetically favored postfusion state. Antibodies that target F can prevent viral entry and reduce disease caused by RSV. During recent years, many prefusion F-specific antibodies have been described. These antibodies typically have stronger RSV-neutralizing activity compared to those that also bind F in the postfusion conformation. Here, we describe how F-specific antibodies protect against RSV and why specifically targeting prefusion F could have great clinical potential.
科研通智能强力驱动
Strongly Powered by AbleSci AI